Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF CLINICAL INFECTIOUS DISEASES   JULY 2016 , Volume 11 , Number 3; Page(s) 0 To 0.
 
Paper: 

EDITORIAL: THE DEBATE OVER TWO-DOSE OR THREE-DOSE HUMAN PAPILLOMAVIRUS VACCINE

 
 
Author(s):  MARDANI MASOUD*
 
* INFECTIOUS DISEASES AND TROPICAL MEDICINE RESEARCH CENTER, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, I.R. IRAN
 
Abstract: 

Cervical cancer is the fourth most common cancer in women around the world, and HPV types 16 and 18 are responsible for about 70% of cases (1). The HPV vaccine was initially developed in 2006 to be given in three doses over six months, but many countries are now moving to a twodose schedule for adolescents (2).

 
Keyword(s): HPV, VACCINE, CERVICAL CANCER CERVICAL CANCER
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 193
 
Latest on Blog
Enter SID Blog